Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2011

View Archived Issues

Aspirin lowers risk of colorectal cancer in Lynch syndrome

Recommended phase II dose of serdemetan determined in patients with advanced solid tumors

Fostamatinib shows long-term safety in rheumatoid arthritis

Merck & Co. reports progress of third quarter 2011

Amgen announces highlights of third quarter 2011

Eisai starts phase I trial of candidate insomnia therapy

Enrollment begins in Genetech's phase II GDC-0980 trial in endometrial cancer

Celldex Therapeutics begins phase I trial of CDX-1127

Avir Green Hills Biotechnology reports on flu vaccine

Calcium-activated K(Ca)1.1 potassium channel activator shows promise in model of bladder dysfunction

PROVIDE trial examines boceprevir in patients with refractory hepatitis C

Study assesses dose-response relationship of arthritis therapy

Novel antitumor compound prepared at Chinese university

Access Pharmaceuticals signs agreement for RNAi delivery technology

FDA accepts MoxDuo IR NDA for review

New tranylcypromine derivatives designed in Italy

Children's Hospital Boston and Pfizer to research muscular dystrophy therapeutics

Merck & Co. launches Nexplanon in U.S.

Peking University synthesizes novel agents to treat cancer

Sinovac reports preliminary phase II data on vaccine for hand, foot and mouth disease

Unigene discloses topline phase II data on oral parathyroid hormone analogue

Merck & Co. claims new products for anemia

Dako and BMS build on pharmacodiagnostics collaboration

MIT discloses novel targeted siRNA nanocomplexes for ovarian cancer

Sanofi and Regeneron report on phase II hypercholesterolemia program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...